Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer

Kevin Albuquerque, Mona Patel, Margaret Liotta, Matthew Harkenrider, Rong Guo, William Small, Potkul Ronald

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objectives This study aimed to report on long-term effectiveness of involved field radiation therapy (IFRT) in the salvage of localized recurrent ovarian cancer (ROC). Methods A retrospective analysis of 27 patients with a diagnosis of epithelial ovarian cancer who received tumor volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation after cytoreductive surgery (CRS) or as attempted salvage if unresectable) forms the basis of this report. All patients were heavily pretreated with multiple chemotherapy regimens. Involved field radiation therapy was primarily with external beam (median dose, 50.4 Gy). Local recurrence-free survival (LRFS) was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy. Statistical analyses evaluated association between disease-free survival, overall survival, LRFS, and various prognostic factors. Comparison was also made with a similar but unmatched cohort with localized recurrences salvaged by additional chemotherapy instead of local therapies (NIFRT group). Results Of 27 patients, 17 had optimal CRS before RT. The actuarial survival at 5 and 10 years (in parenthesis) from date of radiation were LRFS (70% and 60%), overall survival (30% and 19%), and disease-free survival (33% and 20%). None of the NIFRT patients survived beyond 5 years from initiation of salvage chemotherapy. Conclusions Long-term follow-up in this selected series confirmed the benefit of IFRT (±CRS) in localized ROC. Chemotherapy salvage in a similar NIFRT group was not equivalent, suggesting a role for locoregional therapies in selected patients with ROC.

Original languageEnglish (US)
Pages (from-to)655-660
Number of pages6
JournalInternational Journal of Gynecological Cancer
Volume26
Issue number4
DOIs
StatePublished - May 1 2016

Fingerprint

Tumor Burden
Ovarian Neoplasms
Radiotherapy
Recurrence
Survival
Drug Therapy
Disease-Free Survival
Group Psychotherapy
Radiation

Keywords

  • Cytoreductive surgery
  • Involved field radiation therapy
  • Recurrent ovarian cancer
  • Salvage treatment

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer. / Albuquerque, Kevin; Patel, Mona; Liotta, Margaret; Harkenrider, Matthew; Guo, Rong; Small, William; Ronald, Potkul.

In: International Journal of Gynecological Cancer, Vol. 26, No. 4, 01.05.2016, p. 655-660.

Research output: Contribution to journalArticle

Albuquerque, Kevin ; Patel, Mona ; Liotta, Margaret ; Harkenrider, Matthew ; Guo, Rong ; Small, William ; Ronald, Potkul. / Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer. In: International Journal of Gynecological Cancer. 2016 ; Vol. 26, No. 4. pp. 655-660.
@article{7661ffacefc041429fc031e699fc3b71,
title = "Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer",
abstract = "Objectives This study aimed to report on long-term effectiveness of involved field radiation therapy (IFRT) in the salvage of localized recurrent ovarian cancer (ROC). Methods A retrospective analysis of 27 patients with a diagnosis of epithelial ovarian cancer who received tumor volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation after cytoreductive surgery (CRS) or as attempted salvage if unresectable) forms the basis of this report. All patients were heavily pretreated with multiple chemotherapy regimens. Involved field radiation therapy was primarily with external beam (median dose, 50.4 Gy). Local recurrence-free survival (LRFS) was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy. Statistical analyses evaluated association between disease-free survival, overall survival, LRFS, and various prognostic factors. Comparison was also made with a similar but unmatched cohort with localized recurrences salvaged by additional chemotherapy instead of local therapies (NIFRT group). Results Of 27 patients, 17 had optimal CRS before RT. The actuarial survival at 5 and 10 years (in parenthesis) from date of radiation were LRFS (70{\%} and 60{\%}), overall survival (30{\%} and 19{\%}), and disease-free survival (33{\%} and 20{\%}). None of the NIFRT patients survived beyond 5 years from initiation of salvage chemotherapy. Conclusions Long-term follow-up in this selected series confirmed the benefit of IFRT (±CRS) in localized ROC. Chemotherapy salvage in a similar NIFRT group was not equivalent, suggesting a role for locoregional therapies in selected patients with ROC.",
keywords = "Cytoreductive surgery, Involved field radiation therapy, Recurrent ovarian cancer, Salvage treatment",
author = "Kevin Albuquerque and Mona Patel and Margaret Liotta and Matthew Harkenrider and Rong Guo and William Small and Potkul Ronald",
year = "2016",
month = "5",
day = "1",
doi = "10.1097/IGC.0000000000000653",
language = "English (US)",
volume = "26",
pages = "655--660",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Wolters Kluwer Health",
number = "4",

}

TY - JOUR

T1 - Long-term benefit of tumor volume-directed involved field radiation therapy in the management of recurrent ovarian cancer

AU - Albuquerque, Kevin

AU - Patel, Mona

AU - Liotta, Margaret

AU - Harkenrider, Matthew

AU - Guo, Rong

AU - Small, William

AU - Ronald, Potkul

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Objectives This study aimed to report on long-term effectiveness of involved field radiation therapy (IFRT) in the salvage of localized recurrent ovarian cancer (ROC). Methods A retrospective analysis of 27 patients with a diagnosis of epithelial ovarian cancer who received tumor volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation after cytoreductive surgery (CRS) or as attempted salvage if unresectable) forms the basis of this report. All patients were heavily pretreated with multiple chemotherapy regimens. Involved field radiation therapy was primarily with external beam (median dose, 50.4 Gy). Local recurrence-free survival (LRFS) was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy. Statistical analyses evaluated association between disease-free survival, overall survival, LRFS, and various prognostic factors. Comparison was also made with a similar but unmatched cohort with localized recurrences salvaged by additional chemotherapy instead of local therapies (NIFRT group). Results Of 27 patients, 17 had optimal CRS before RT. The actuarial survival at 5 and 10 years (in parenthesis) from date of radiation were LRFS (70% and 60%), overall survival (30% and 19%), and disease-free survival (33% and 20%). None of the NIFRT patients survived beyond 5 years from initiation of salvage chemotherapy. Conclusions Long-term follow-up in this selected series confirmed the benefit of IFRT (±CRS) in localized ROC. Chemotherapy salvage in a similar NIFRT group was not equivalent, suggesting a role for locoregional therapies in selected patients with ROC.

AB - Objectives This study aimed to report on long-term effectiveness of involved field radiation therapy (IFRT) in the salvage of localized recurrent ovarian cancer (ROC). Methods A retrospective analysis of 27 patients with a diagnosis of epithelial ovarian cancer who received tumor volume-directed IFRT for localized extraperitoneal recurrences (either as consolidation after cytoreductive surgery (CRS) or as attempted salvage if unresectable) forms the basis of this report. All patients were heavily pretreated with multiple chemotherapy regimens. Involved field radiation therapy was primarily with external beam (median dose, 50.4 Gy). Local recurrence-free survival (LRFS) was defined as freedom from in-field recurrences and was considered as a measure of effectiveness of radiotherapy. Statistical analyses evaluated association between disease-free survival, overall survival, LRFS, and various prognostic factors. Comparison was also made with a similar but unmatched cohort with localized recurrences salvaged by additional chemotherapy instead of local therapies (NIFRT group). Results Of 27 patients, 17 had optimal CRS before RT. The actuarial survival at 5 and 10 years (in parenthesis) from date of radiation were LRFS (70% and 60%), overall survival (30% and 19%), and disease-free survival (33% and 20%). None of the NIFRT patients survived beyond 5 years from initiation of salvage chemotherapy. Conclusions Long-term follow-up in this selected series confirmed the benefit of IFRT (±CRS) in localized ROC. Chemotherapy salvage in a similar NIFRT group was not equivalent, suggesting a role for locoregional therapies in selected patients with ROC.

KW - Cytoreductive surgery

KW - Involved field radiation therapy

KW - Recurrent ovarian cancer

KW - Salvage treatment

UR - http://www.scopus.com/inward/record.url?scp=84965138907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965138907&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000000653

DO - 10.1097/IGC.0000000000000653

M3 - Article

C2 - 26825832

AN - SCOPUS:84965138907

VL - 26

SP - 655

EP - 660

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 4

ER -